Mar 30, 2020

Mar 30, 2020

Mar 30, 2020

Model Medicines COVID-19 Drug Development Program Highlighted by Catalyst Health 2.0

Health Tech Responds to COVID-19

The Health Tech Responds to COVID-19 website is a production of Catalyst @ Health 2.0 (“Catalyst”). We believe in digital health’s ability to facilitate the response to COVID-19 and are committed to providing current information and resources on the digital health ecosystem’s response. Catalyst’s global network of health information technology entrepreneurs, software developers, health care provider and payer organizations, pharmaceutical companies, philanthropic foundations, physicians, and government representatives are utilizing their resources to address the virus. 

Read More

This article originally appeared on Catalyst @ Health 2.0 (“Catalyst”), prior to the rebrand of Repurpose.AI to Model Medicines, read the full article here.

Details

Date

Mar 30, 2020

Category

Press

Reading

2 Mins

Author

Patrick ONeill

Investor Relations

Related News

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases